Efficacy and safety of adrenocorticotropic hormone gel in refractory dermatomyositis and polymyositis

医学 多发性肌炎 耐受性 内科学 皮肌炎 青少年皮肌炎 临床终点 不利影响 痹症科 强的松 耐火材料(行星科学) 临床试验 胃肠病学 物理 天体生物学
作者
Rohit Aggarwal,Galina Marder,Diane Koontz,Preeya Nandkumar,Zengbiao Qi,Chester V. Oddis
出处
期刊:Annals of the Rheumatic Diseases [BMJ]
卷期号:77 (5): 720-727 被引量:50
标识
DOI:10.1136/annrheumdis-2017-212047
摘要

Aim To evaluate the efficacy, safety, tolerability and steroid-sparing effect of repository corticotropin injection (RCI), in an open-label clinical trial, in refractory adult polymyositis (PM) and dermatomyositis (DM). Methods Adults with refractory PM and DM were enrolled by two centres. Inclusion criteria included refractory disease defined as failing glucocorticoid and/or ≥1 immunosuppressive agent, as well as active disease defined as significant muscle weakness and >2 additional abnormal core set measures (CSMs) or a cutaneous 10 cm Visual Analogue Scale score of ≥3 cm and at least three other abnormal CSMs. All patients received RCI of 80 units subcutaneously twice weekly for 24 weeks. The primary end point for the trial was the International Myositis Assessment and Clinical Studies definition of improvement. Secondary end points included safety, tolerability, steroid-sparing as well as the 2016 American College of Rheumatology (ACR)/European League Against Rheumatism myositis response criteria (EULAR) Results Ten of the 11 enrolled subjects (6 DM, 4 PM) completed the study. Seven of 10 met the primary end point of efficacy at a median of 8 weeks. There was a significant decrease in prednisone dose from baseline to conclusion (18.5 (15.7) vs 2.3 (3.2); P<0.01). Most individual CSMs improved at week 24 compared with the baseline, with the muscle strength improving by >10% and the physician global by >40%. RCI was considered safe and tolerable. No patient developed significant weight gain or an increase of haemoglobin A1c or cushingoid features. Conclusion Treatment with RCI was effective in 70% of patients, safe and tolerable, and led to a steroid dose reduction in patients with adult myositis refractory to glucocorticoid and traditional immunosuppressive drugs. Trial registration number NCT01906372 ; Results.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
trouble虫虫完成签到,获得积分10
1秒前
kiki完成签到,获得积分10
1秒前
xzx发布了新的文献求助10
2秒前
苹果桐完成签到,获得积分10
2秒前
秋风的应助被无趣采纳,获得10
4秒前
脑洞疼的应助被无趣采纳,获得10
4秒前
sufu_jony的应助被无趣采纳,获得10
4秒前
4秒前
4秒前
满意妙梦发布了新的文献求助10
4秒前
5秒前
fy发布了新的文献求助10
5秒前
活力的幻露完成签到,获得积分10
6秒前
我是老大的应助被明亮白山采纳,获得10
7秒前
9秒前
隐形曼青的应助被现代胡萝卜采纳,获得30
9秒前
榴莲发布了新的文献求助10
10秒前
学习发布了新的文献求助10
10秒前
穆有问题完成签到,获得积分10
11秒前
英姑的应助被初景采纳,获得150
11秒前
调皮芝麻完成签到,获得积分10
11秒前
11秒前
SciGPT的应助被哈基米德采纳,获得10
12秒前
赘婿的应助被羡鱼采纳,获得10
12秒前
Eliauk发布了新的文献求助50
12秒前
板凳饭团完成签到,获得积分10
13秒前
Nole的应助被11采纳,获得30
15秒前
DW的应助被Olive采纳,获得10
15秒前
16秒前
16秒前
满意妙梦完成签到,获得积分10
16秒前
无趣完成签到,获得积分20
17秒前
17秒前
一生所爱发布了新的文献求助10
18秒前
ff完成签到,获得积分10
18秒前
xiejingyu发布了新的文献求助10
19秒前
酷波er的应助被DREAMING采纳,获得10
19秒前
19秒前
刘刘宇航完成签到,获得积分20
21秒前
濯枝雨完成签到 ,获得积分10
21秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183694
求助须知:如何正确求助?哪些是违规求助? 9572963
关于积分的说明 21828306
捐赠科研通 7780864
什么是DOI,文献DOI怎么找? 3434057
关于科研通互助平台的介绍 2558257
邀请新用户注册赠送积分活动 2480541